var _paq = window._paq = window._paq || []; /* tracker methods like "setCustomDimension" should be called before "trackPageView" */ _paq.push(['trackPageView']); _paq.push(['enableLinkTracking']); (function() { var u="https://rwrregs.matomo.cloud/"; _paq.push(['setTrackerUrl', u+'matomo.php']); _paq.push(['setSiteId', '1']); var d=document, g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.data-privacy-src='//cdn.matomo.cloud/rwrregs.matomo.cloud/matomo.js'; s.parentNode.insertBefore(g,s); })();

Poland – The Journey towards Real World Evidence and Digital Transformation

RWE 201 – Poland – The Journey towards Real World Evidence and Digital Transformation

 

Real World Evidence (RWE) and Real World Data (RWD) initiatives in Poland are still in the early stages of development, but there is a growing interest and recognition of their potential benefits. Key stakeholders in Poland have not yet fully embraced RWE as an evidence source, but there is a growing need for more evidence to allocate scarce resources. There is significant interest among physicians in practical evidence and a broad spectrum of possible actions that can be undertaken to improve the formal use of RWE in Poland. However, creating databases (registers) requires considerable financial and organisational effort, which creates a significant impediment to the effective development of RWE in Poland.

In terms of the implementation of the European Health Data Space (EHDS), Poland has shown support for the proposal, emphasizing that EHDS will contribute to the digitization of the healthcare sector in Poland. The patients will gain more rights when it comes to the control of their health data. Poland’s experience after engaging in the cross-border exchange of e-prescriptions and creating the COVID-19 certificate is very positive, giving prospects for the development of EHDS.

Poland has also adopted SNOMED CT as part of its digital health transformation. The country’s e-Health Centre, which implements key IT projects for the healthcare system, will represent Poland at SNOMED International. The renewed adoption of SNOMED CT in Poland will support the realization of another key element of the country’s strategy – ensuring that medical professionals are able to electronically document and easily share patient data.

However, there are challenges to overcome in obtaining RWD. These include the multitude of data sources, the need for a different process for RWD compared to clinical trials, ensuring the study is representative of real-life, managing research-naïve sites, and using the right tools.

In summary, while there are challenges to overcome, Poland is making strides in implementing RWE and RWD initiatives to support the implementation of the EHDS. The country is taking steps to digitize its healthcare sector, improve patient rights to health data, and facilitate the sharing of patient data among medical professionals. These initiatives are expected to contribute to the improvement of healthcare outcomes and the efficient allocation of resources in the country.

Share this story...
Real World Evidence (RWE) 201 – Germany’s Draft Health Data Usage Act

December 8, 2023|2023, RWE 201|

RWE 201 - Germany's Draft Health Data Usage Act   Draft Health Data Usage Act (GDNG): https://www.bundesgesundheitsministerium.de/service/gesetze-und-verordnungen/detail/gesundheitsdatennutzungsgesetz.html BfArM Health Research Data Center: https://www.bfarm.de/DE/Das-BfArM/Aufgaben/Forschungsdatenzentrum/_node.html In June 2023, the [...]

Poland – The Journey towards Real World Evidence and Digital Transformation2023-11-05T13:02:30+00:00

Latvia – Making Early Strides to Implement RWE and RWD Initiatives

RWE 201 – Latvia – Making Early Strides to Implement RWE and RWD Initiatives

 

Latvia is actively working on initiatives to implement Real-World Evidence (RWE) and Real-World Data (RWD) in its healthcare system, with a focus on improving healthcare decision-making and enhancing the use of health technology assessment.

The Innovative Medicines Initiative (IMI) has set up the GetReal Initiative project to drive the adoption of RWE in healthcare decision-making across Europe, including Latvia. This initiative aims to tackle challenges related to data discoverability, quality, and accessibility, and bridge the gap between RWE and conventional randomised controlled trial approaches. It also offers education and training resources through the GetReal Academy.

In Latvia, there is no formal requirement for RWD submission within the reimbursement dossier. The evidence required for the decision-making process should be collected through randomized controlled clinical trials and is considered for decisions only when the results are published. However, RWD can be a supportive argument for decision-makers. The Center of Disease Prevention and Control (CDPC) is the main institution responsible for collecting and summarizing all health-related data in Latvia.

The European Commission is supporting Latvia with projects in the areas of development of public sector innovation and digitalisation, including improving the use of health technology assessment in decision-making. This support has addressed a broad range of policy areas, including healthcare, better governance and public administration, and justice.

Latvia could still stand to increase the use of real-world healthcare data to inform biomedical research and evaluation. A “learning healthcare system” based on electronic health records and other routinely collected data holds large promises for facilitating medical research and improving effective and efficient use of medicines, is at an early stage in Latvia.

In conclusion, while Latvia has made strides in implementing RWE and RWD initiatives, there is still room for growth and development in this area. The country is actively participating in European-wide initiatives and projects to enhance the use of RWE and RWD in healthcare decision-making and is working towards a learning healthcare system that leverages these data sources.

Share this story...
Real World Evidence (RWE) 201 – Germany’s Draft Health Data Usage Act

December 8, 2023|2023, RWE 201|

RWE 201 - Germany's Draft Health Data Usage Act   Draft Health Data Usage Act (GDNG): https://www.bundesgesundheitsministerium.de/service/gesetze-und-verordnungen/detail/gesundheitsdatennutzungsgesetz.html BfArM Health Research Data Center: https://www.bfarm.de/DE/Das-BfArM/Aufgaben/Forschungsdatenzentrum/_node.html In June 2023, the [...]

Latvia – Making Early Strides to Implement RWE and RWD Initiatives2023-11-05T12:58:02+00:00

Lithuania – Leaping into Digital Health Future with RWE and RWD Innovations

RWE 201 – Lithuania – Leaping into Digital Health Future with RWE and RWD Innovations

 

EU Partnership Agreement: https://ec.europa.eu/commission/presscorner/detail/en/ip_22_2547

Lithuania is actively implementing Real-World Evidence (RWE) and Real-World Data (RWD) initiatives to support the implementation of the European Health Data Space (EHDS). These initiatives are aimed at improving healthcare provision, fostering innovation, and enhancing personalized healthcare through the secondary use of health data.

One of the key initiatives in Lithuania is the development of a national health record system. This system (created by Nortal) has transformed the nation’s healthcare landscape by digitizing and standardizing health records. This has not only reduced administrative burdens and costs but also improved transparency and opened up new opportunities for development.

In addition, Lithuania has been working on the creation of a Health Technology Assessment (HTA) system and strategy. This initiative, supported by EU funds, aims to integrate a systematic and long-term approach to HTA into the health system. The Lithuanian HTA strategy addresses the needs of a health system that is still highly centralized and governed by the Ministry of Health.

Furthermore, Lithuania is part of the EU’s €6.4 billion Partnership Agreement for 2021-2027, which will help implement country-specific recommendations in the context of the European Semester. This includes reforms and investments in healthcare, among other sectors.

The secondary use of health data is recognized as essential to realize the potentials for high-quality healthcare, improved healthcare management, reduced healthcare costs, population health management, and effective clinical research. The most common secondary use of health data today is research, which is greatly facilitated by better access to registries and other health data sources.

However, the implementation of RWE and RWD initiatives also presents challenges, particularly in terms of data security and compliance with industry-specific regulations. Therefore, prioritizing data security measures and implementing robust cybersecurity strategies are crucial.

In conclusion, Lithuania’s RWE and RWD initiatives are part of a broader effort to improve healthcare provision and outcomes, foster innovation, and enhance personalized healthcare. These initiatives are aligned with the goals of the EHDS, which aims to facilitate the exchange of health data across the EU to improve healthcare provision and outcomes.

Share this story...
Real World Evidence (RWE) 201 – Germany’s Draft Health Data Usage Act

December 8, 2023|2023, RWE 201|

RWE 201 - Germany's Draft Health Data Usage Act   Draft Health Data Usage Act (GDNG): https://www.bundesgesundheitsministerium.de/service/gesetze-und-verordnungen/detail/gesundheitsdatennutzungsgesetz.html BfArM Health Research Data Center: https://www.bfarm.de/DE/Das-BfArM/Aufgaben/Forschungsdatenzentrum/_node.html In June 2023, the [...]

Lithuania – Leaping into Digital Health Future with RWE and RWD Innovations2023-11-05T12:47:01+00:00

RWE Guest Post – Does Real-World Evidence Play a Role in G-BA’s Benefit Assessments in Germany?

RWE 201 – RWE Guest Post – Does real-world evidence play a role in G-BA’s benefit assessments in Germany?

 

Guest: Anja Pownell

German Market Access – Simplified: https://germanmarketaccesssimplified.com/

Introduction

The German Federal Joint Committee (G-BA), responsible for assessing the additional benefits of healthcare interventions, theoretically, has a relatively new tool at its disposal to make more informed decisions. Since 2020, G-BA has had the authority to request real-world evidence (RWE) data collection for certain products, providing a valuable addition to the traditional clinical trial data used in benefit assessments.

Real-World Evidence Data Collection requested by the G-BA

Some drugs, such as those with conditional approval, those authorized under exceptional circumstances, or orphan drugs, receive regulatory approval under special statuses. These approvals aim to make these treatments available to patients quickly, often leading to a lack of mature or sufficient data for conventional benefit assessments.

In these cases, the G-BA can request that manufacturers collect RWE on their use in routine clinical practice, a process known as “Anwendungsbegleitende Datenerhebung.” The G-BA can request this data collection from the manufacturer immediately upon market entry of a new drug or at a later time point. This data collection ensures better, more relevant information becomes available as patients receive the product in daily German clinical practice.

After several years, the G-BA re-evaluates the drug, incorporating the collected RWE alongside data from clinical trials. This comprehensive evaluation is intended to help the G-BA make more informed decisions regarding the additional benefit. Currently, RWE collection is underway for only two products, highlighting the novelty of this approach:

– Zolgensma in spinal muscle atrophy, final data expected by 2027.

– Tecartus in relapsed/refractory mantle cell lymphoma, final data expected in 2028.

The need and feasibility of RWE collection are being assessed for another 8 products.

Thus, it is too early to fully understand the role RWE will play in G-BA’s decision-making. These first re-assessments after RWE collection in 2027 or 2028 will undoubtedly provide valuable insights into how the G-BA will deal with the non-comparative RWE.

The Future of RWE in G-BA’s Decision-Making

As we move forward, it will be interesting to see how the utilization of RWE in benefit assessments evolves and expands, offering more insights and maintaining a high level of transparency in the decision-making process within the German healthcare system.

[Source: G-BA – Anwendungsbegleitende Datenerhebung] (https://www.g-ba.de/themen/arzneimittel/arzneimittel-richtlinie-anlagen/anwendungsbegleitende-datenerhebung/)

Share this story...
Real World Evidence (RWE) 201 – Germany’s Draft Health Data Usage Act

December 8, 2023|2023, RWE 201|

RWE 201 - Germany's Draft Health Data Usage Act   Draft Health Data Usage Act (GDNG): https://www.bundesgesundheitsministerium.de/service/gesetze-und-verordnungen/detail/gesundheitsdatennutzungsgesetz.html BfArM Health Research Data Center: https://www.bfarm.de/DE/Das-BfArM/Aufgaben/Forschungsdatenzentrum/_node.html In June 2023, the [...]

RWE Guest Post – Does Real-World Evidence Play a Role in G-BA’s Benefit Assessments in Germany?2023-11-05T12:43:00+00:00

RWE Guest Post – Germany – From Concept to Evaluation: The Journey of RWE requests by the G-BA

RWE 201 – RWE Guest Post – Germany – From Concept to Evaluation: The Journey of RWE requests by the G-BA

 

Guest: Anja Pownell

German Market Access – Simplified: https://germanmarketaccesssimplified.com/

Introduction

Since 2020, the German Federal Joint Committee (G-BA) can request real-world evidence (RWE) to enhance its decision-making, as a crucial complement to traditional clinical trial data, for drugs that received regulatory approval under special statuses.

The process of requested RWE collection is meticulous and involves several key steps:

  1. Plenum Determination: The G-BA plenum decides whether RWE collection is necessary for a specific drug.
  2. Draft Concept Development: Within the next six months, the G-BA or IQWiG develops a draft concept that outlines the data collection’s specifics, including type, duration, extent, key questions, data collection methods, and data evaluation.
  3. External Expert Input: The G-BA shares the draft concept with external experts, including the Federal Institute for Drugs and Medical Devices (BfArM), the Paul-Ehrlich-Institute (PEI), medical societies, the Drug Commission of the German Medical Association (AkdÄ), and the manufacturer, for their input.
  4. Finalization of the Concept Plan: The G-BA plenum finalizes the concept plan within the next 6 months, ensuring that it covers all aspects of data collection. In some cases, the G-BA may restrict reimbursement to clinicians participating in the data collection, ensuring comprehensive data coverage.
  5. Data Collection and Evaluation: The manufacturer is then responsible for conducting the study, which can involve setting up new studies or utilizing existing registries to capture the required data. The manufacturer evaluates the collected data and shares the analyses with G-BA.
  6. Periodic Assessments: Every 1.5 years, the G-BA assesses the progress of data collection, evaluating whether the data collection is proceeding as planned, whether the data is sufficient for a benefit re-assessment, and whether any amendments to the concept plan are needed to enhance data meaningfulness.

The Role of IQWiG

With the introduction of the RWE collection requests, in 2020, the Institute for Quality and Efficiency in Health Care (IQWiG) developed criteria and detailed recommendations for manufacturers and registries on how to supplement the trial data with RWE (German: “Versorgungsnahe Daten”), such as registry data. If the RWE is of high quality, the IQWiG and G-BA can use it to determine the additional benefit of an intervention outside of a clinical trial.

According to IQWiG, “manufacturers don’t interpret the detailed requirements on RWE collection how we wish they did. Overall, the problems often were missing key information and differences between patient populations. It was not possible to conduct a meaningful benefit assessment with the data. Manufacturers often did identify the problems themselves but did not draw the necessary consequences.”

Share this story...
Real World Evidence (RWE) 201 – Germany’s Draft Health Data Usage Act

December 8, 2023|2023, RWE 201|

RWE 201 - Germany's Draft Health Data Usage Act   Draft Health Data Usage Act (GDNG): https://www.bundesgesundheitsministerium.de/service/gesetze-und-verordnungen/detail/gesundheitsdatennutzungsgesetz.html BfArM Health Research Data Center: https://www.bfarm.de/DE/Das-BfArM/Aufgaben/Forschungsdatenzentrum/_node.html In June 2023, the [...]

RWE Guest Post – Germany – From Concept to Evaluation: The Journey of RWE requests by the G-BA2023-11-05T12:37:59+00:00

Spain – Championing the Ethical and Responsible Use of Real World Data

RWE 201 – Spain – Championing the Ethical and Responsible Use of Real World Data

 

Farmindustria Code of Conduct: https://codigoprotecciondatos.farmaindustria.org/sites/medicamentosinnovadores/docs/PRODF484450.pdf

In 2022, the Spanish Data Protection Agency (AEPD) gave its stamp of approval to the Farmaindustria “Code of Conduct regulating the processing of personal data in the field of clinical trials and other clinical research and pharmacovigilance.” These self-regulation standards focus on clinical studies involving medicines and are designed to help study sponsors understand the appropriate application of data protection regulations.

Support for Real-World Data and Evidence

This code of conduct acknowledges the significance of real-world data (RWD), which covers a broad spectrum of patient health information sourced from routine clinical practice, patients’ records, and even data acquired from wearable devices. Real-world evidence derived from this data is pivotal for observational studies with medicinal products. Such studies are instrumental in identifying the therapeutic effects of drugs, understanding adverse reactions, and gaining insights into medicine usage patterns without disrupting conventional clinical procedures.

Key Provisions from the Code of Conduct:

  1. Data Protection Impact Assessment (DPIA): Before the commencement of any clinical research, a thorough DPIA must be undertaken. This ensures that the data processing activities associated with the research are assessed for potential risks to participants’ rights and freedoms. If the assessment indicates high, unmitigated risks, relevant data protection authorities must be consulted prior to starting the research.
  1. Consent Stipulations: For any intended reuse of a participant’s data, a legitimate basis in line with data protection laws is mandatory. If the reuse involves coded data, it might not necessitate new consent, provided that certain regulatory stipulations are met, including robust security measures and a commitment to prevent re-identification.
  2. Broad Consent: Given the dynamic nature of clinical research, where full identification of data processing purposes might be challenging, participants can be approached for broad consent. This allows their data to be used for broader areas of investigation related to the original study. However, it’s imperative to keep participants informed, respect data protection principles, and secure necessary authorizations.

The comprehensive code of conduct provides clarity on various terminologies, from “patient’s records” to “trusted third party” and underscores the obligatory nature of the code for entities that choose to adhere. By fostering a standardized approach to data protection in clinical research, the code champions the ethical and responsible use of RWD, promoting transparency, trust, and advancing the field of medicine.

Share this story...
Real World Evidence (RWE) 201 – Germany’s Draft Health Data Usage Act

December 8, 2023|2023, RWE 201|

RWE 201 - Germany's Draft Health Data Usage Act   Draft Health Data Usage Act (GDNG): https://www.bundesgesundheitsministerium.de/service/gesetze-und-verordnungen/detail/gesundheitsdatennutzungsgesetz.html BfArM Health Research Data Center: https://www.bfarm.de/DE/Das-BfArM/Aufgaben/Forschungsdatenzentrum/_node.html In June 2023, the [...]

Spain – Championing the Ethical and Responsible Use of Real World Data2023-11-05T12:33:16+00:00

EU – RWD/RWE is Embedded into the New EU Medicines Regulations

RWE 201 – EU – RWD/RWE is Embedded into the New EU Medicines Regulations

 

Coming Soon…New EU Medicines Regulations: https://health.ec.europa.eu/medicinal-products/pharmaceutical-strategy-europe/reform-eu-pharmaceutical-legislation_en

In 2023, the European Commission undertook an ambitious overhaul of its pharmaceutical regulations. This revision addresses foundational pharmaceutical legislation, specifically Regulation 726/2004, Directive 2001/83/EC, and rules for medicines tailored for children and rare diseases, namely Regulation 1901/2006 and Regulation 141/2000/EC.

Primary Aims:

– Ensure all EU patients access safe, effective, and affordable medicines promptly and fairly.

– Bolster medicine supply security across the EU.

– Propagate an innovation-centric environment for medicine R&D in Europe.

– Pivot towards environmentally sustainable medicines.

– Confront antimicrobial resistance and environmental pharmaceutical contamination through a holistic One Health approach.

Key Points of the Revision:

  1. Individual Patient Data: Regulators can now request structured individual patient data from clinical studies, promoting data-driven benefit-risk assessments for medicines throughout their life cycle (Recital 63 of MP-R).
  2. Transparency of Public Support: There’s now a mandate to disclose any direct financial backing received from public authorities for medicine R&D, fostering accountability and transparency (Recital 131 of MP-D).
  3. Patient Representation: The CHMP (Committee for Medicinal Products for Human Use) and PRAC (Pharmacovigilance Risk Assessment Committee) now include patient representatives, enriching patient voices in decisions.
  4. Real World Data (RWD): The revision endorses the use of health data, particularly RWD, for regulatory decision-making. Through systems like the DARWIN and European Health Data Space infrastructure, the agency can harness supercomputing, AI, and big data without jeopardizing privacy (Recital 60 of MP-R).
  5. Regulatory Sandbox: This introduces a controlled setting wherein innovative regulatory solutions can be tested, cultivated, and authenticated under scrutiny (Articles 2(12), 113-155 of MP-R).
  6. Compassionate Use Programs: Provisions for these programs, which offer early medicinal product access, have been strengthened. It’s vital to collect data from these programs to evaluate the benefit-risk ratio of medicines (Recital 57 & Article 26(4) of MP-R).
  7. Comparative Effectiveness: By repurposing medicines and leveraging comparative trial data, patients will have expedited access to novel treatments. Such data assists authorities in ascertaining a medicine’s cost-effectiveness.
  8. Relative Effectiveness: The EU has devised a scientific, evidence-based methodology to gauge the relative effectiveness of medicinal products. This focuses on a medicine’s added value against other health technologies but doesn’t extend to its marketing authorization (Recital 130 of MP-R).

In essence, this legislative revamp by the European Commission fosters a more patient-centric, transparent, and data-driven approach in the EU pharmaceutical landscape.

Share this story...
Real World Evidence (RWE) 201 – Germany’s Draft Health Data Usage Act

December 8, 2023|2023, RWE 201|

RWE 201 - Germany's Draft Health Data Usage Act   Draft Health Data Usage Act (GDNG): https://www.bundesgesundheitsministerium.de/service/gesetze-und-verordnungen/detail/gesundheitsdatennutzungsgesetz.html BfArM Health Research Data Center: https://www.bfarm.de/DE/Das-BfArM/Aufgaben/Forschungsdatenzentrum/_node.html In June 2023, the [...]

EU – RWD/RWE is Embedded into the New EU Medicines Regulations2023-11-05T12:28:42+00:00

EU – EU’s Action Plan for Real-World Data (RWD) & RWE

RWE 201 – EU – EU’s Action Plan for Real-World Data (RWD) & RWE

 

The European Union has embarked on an ambitious journey to weave Real World Evidence (RWE) into the fabric of its healthcare system. The strategy, underscored by a comprehensive multi-year plan, focuses on harnessing the power of real-world data (RWD) through collaboration, standardization, and innovation. The infrastructure for this integration outlines seven pivotal components: Terminology, Findability, Access, Quality, Advanced Analytics, Use, and Use Cases.

 

RWE 2020 – The Foundation: The EU emphasizes on the importance of RWD Collection and RWE Generation. Key pillars of this foundational year include:

– Enhancing collaboration nationally and across borders.

– Creating a robust framework with effective methodologies.

– Recognizing the role of RWE in supplementing clinical trials.

– Aiming to support decisions by regulators, HTA, and payers.

– Advocating support for healthcare providers.

 

2021:

– Focuses on access to RWD and the establishment of the EU4Health Program.

– Introduction of new legislations: Artificial Intelligence Regulation, Health Technology Assessment Regulation, and laws on RWE Value and RWD Access.

– Notably, a step towards centralized data governance with the European Health Data Space Regulation.

 

2022:

– Expands on the RWE Use Cases with guidelines and draft laws.

– Emphasis on medicinal product regulations.

– The Data Governance Act aims to support data access and streamline data utilization.

 

2023:

– Proliferation of RWE use cases continues.

– Medicinal Products Regulation is in the limelight alongside explorations into single-arm trials by EMA.

– The year marks a notable focus on AI with the EMA’s guidance on Artificial Intelligence.2024:

– The direction is set towards advanced RWD analytics and a broader scope of RWE Use Cases.

– Introduces a Catalogue of NIS using RWD Sources and a focus on RWD findability with source catalogues = The replacement for the EU PAS Register

 

This roadmap not only outlines the EU’s commitment to innovative healthcare solutions but also sets a precedent for global health systems to leverage real-world data and evidence for enhanced patient care.

Share this story...
Real World Evidence (RWE) 201 – Germany’s Draft Health Data Usage Act

December 8, 2023|2023, RWE 201|

RWE 201 - Germany's Draft Health Data Usage Act   Draft Health Data Usage Act (GDNG): https://www.bundesgesundheitsministerium.de/service/gesetze-und-verordnungen/detail/gesundheitsdatennutzungsgesetz.html BfArM Health Research Data Center: https://www.bfarm.de/DE/Das-BfArM/Aufgaben/Forschungsdatenzentrum/_node.html In June 2023, the [...]

EU – EU’s Action Plan for Real-World Data (RWD) & RWE2023-11-05T12:24:00+00:00

EU – EMA RWE Framework to Support Regulatory Decision Making

RWE 201 – EU – EMA RWE Framework to Support Regulatory Decision Making

 

EMA RWE Framework 2023: https://www.ema.europa.eu/en/documents/report/real-world-evidence-framework-support-eu-regulatory-decision-making-report-experience-gained_en.pdf

The European Medicine Agency (EMA) is actively working on creating a framework that will facilitate the use and establishes the value of RWE in decision-making throughout the entire drug lifecycle.

The current framework includes 3 evidence generation pathways: (1) In-house database e.g., The Health Improvement Network (THIN®), (2) DARWIN-EU, and (3) ‘Traditional’ primary data studies.

80% of the database studies, also referred to as ‘rapid data analytics’ , were delivered in less than 90 days.  Whereas delivery of the DARWIN-EU studies averaged 215 days. The majority of the studies focused on safety, rare diseases, and paediatrics. 

Key Learning

  1. Suitability of RWD Sources:

– RWD aids in enhancing evidence from clinical trials, aiding EU regulatory decisions.

– Most suitable studies addressed primary care scenarios due to available databases.

  1. Regulatory Context & Timelines:

– Comprehending regulatory nuances and evidence gaps is crucial for apt data selection and study design.

– In-house studies, given their speed, fit well with research questions having tight timelines.

  1. Building Capability & Capacity:

– Familiarity with RWD concepts, methodologies, and terms is essential for RWE acceptance.

  1. Usefulness for Decision-making:

– RWD studies bolster scientific evaluations in multiple regulatory situations.

– Understanding data source attributes aids in grasping study strengths, limitations, and RWE’s value.

  1. Other Process-related Aspects:

– Standardizing RWD study approaches, through agreed processes and templates, enhances RWE efficiency.

Recommendations

  1. RWD Source Expansion: Access more diverse data sources for better representation. Retain all three RWE pathways and collaborate with NCAs to maximize RWE generation.
  2. Enhance RWE Timeliness: Adopt proactive RWD study identification methods and increase RWE generation speed, possibly via tools like DARWIN EU.
  3. Boosting Capability & Capacity: Implement the Big Data Steering Group’s curriculum specifically for regulatory stakeholders.
  4. Improving Decision-making Utility: Detail strengths and limitations in future reports for improved interpretation.
  5. Process Refinement: Encourage reflections on RWE’s potential to bridge knowledge gaps and further unify processes.

Conclusions

Over the report’s timeframe, 27 regulator-led RWD studies were finalized, aiding various regulatory assessments like PRAC and SAWP. These studies spanned across safety, drug use, disease epidemiology, and more, primarily providing descriptive analyses. Some comparative analyses were also done. The range and design of these studies highlight the vast potential of the existing RWE resources and the Agency’s adaptability in addressing diverse research inquiries. However, further enhancements can be made to fully harness the EMA RWD study framework’s potential.

Share this story...
Real World Evidence (RWE) 201 – Germany’s Draft Health Data Usage Act

December 8, 2023|2023, RWE 201|

RWE 201 - Germany's Draft Health Data Usage Act   Draft Health Data Usage Act (GDNG): https://www.bundesgesundheitsministerium.de/service/gesetze-und-verordnungen/detail/gesundheitsdatennutzungsgesetz.html BfArM Health Research Data Center: https://www.bfarm.de/DE/Das-BfArM/Aufgaben/Forschungsdatenzentrum/_node.html In June 2023, the [...]

EU – EMA RWE Framework to Support Regulatory Decision Making2023-11-05T12:17:32+00:00

EU – EMA’s 2025 Vision for RWE

RWE 201 – EU – EMA’s 2025 Vision for RWE

 

EMA 2025 Vision: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299492/

EMA RWE Framework Report: https://www.ema.europa.eu/en/documents/report/real-world-evidence-framework-support-eu-regulatory-decision-making-report-experience-gained_en.pdf

The European Medicines Agency (EMA) isn’t simply relying on RWE submissions from companies. They’ve proactively embarked on developing the DARWIN EU framework, providing access to real-world data (RWD), enabling them to validate study designs, confirm disease prevalence for paediatric waivers, orphan drug designations, and more.

By 2025, EMA aims to:

  1. Fully integrate the use of RWE.
  2. Establish its value across all regulatory domains.

RWE and RWD are not novelties in the EU’s medicinal regulation. While their roles in safety monitoring and disease epidemiology are well-established, their evidentiary worth, especially for efficacy demonstration, is under continued assessment.

Key Developments:

[1] DARWIN EU: Launched in 2022, funded by the EU4Health program, it’s an EU-wide RWD network. It facilitates high-quality studies pivotal for regulatory decisions…by and for the EMA.

[2] RWE Framework Report (June 2023): The EMA detailed how RWE aids in:

– Designing and gauging the feasibility of upcoming studies.

– Ensuring representativeness and validity of completed research.

– Gauging disease prevalence and incidence.

– Understanding clinical management practices.

– Monitoring drug utilization in real-world scenarios.

– Evaluating the efficacy and safety of medical measures.

– Measuring the effectiveness of risk minimisation measure.

Significance: The COVID-19 pandemic highlighted the importance of RWE, as regulators utilized RWD to monitor the safety and efficacy of treatments. This emphasizes the regulator’s role, not just as a gatekeeper but as an adept analyst of RWE. The European Medicine Regulators Network (EMRN) recognizes this, investing in enhancing the skills of its workforce through recruitment, dedicated training, and promoting best practices.

In summary, RWE (generated from RWD) provides the EMA with a practical perspective on medical interventions in real-life scenarios, becoming indispensable in its regulatory role.

Given the EMA’s proactive stance on integrating RWE into their regulatory processes, how is your organization adapting its drug development strategies to ensure you’re not only keeping pace but also leveraging the full potential of real-world evidence?

Share this story...
Real World Evidence (RWE) 201 – Germany’s Draft Health Data Usage Act

December 8, 2023|2023, RWE 201|

RWE 201 - Germany's Draft Health Data Usage Act   Draft Health Data Usage Act (GDNG): https://www.bundesgesundheitsministerium.de/service/gesetze-und-verordnungen/detail/gesundheitsdatennutzungsgesetz.html BfArM Health Research Data Center: https://www.bfarm.de/DE/Das-BfArM/Aufgaben/Forschungsdatenzentrum/_node.html In June 2023, the [...]

EU – EMA’s 2025 Vision for RWE2023-11-05T12:19:04+00:00
Help

About Us

Contact Us

Our Values

SSO Login

Follow Us

Newsletter

LinkedIn

[…]

Legal Info

Privacy Policy

Terms and Conditions

Copyright 2024 | Real-World Research Limited | All Rights Reserved |

This website uses cookies and third party services. Settings OK Reject

Cookies

We use analytical tools (Google Analytics) to help us improve the user experience. We DO NOT sell or use any of this data for any purpose beyond improving the design and usability of our own website (rwr-regs.com).
Go to Top